Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02

Response Assessment in Neuro-Oncology Clinical Trials

(2017) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study

(2017) Andrew Yu et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

(2013) E. Galanis et al.   CLINICAL CANCER RESEARCH

NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme

(2013) David M. Peereboom et al.   NEURO-ONCOLOGY

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02

(2012) E. Q. Lee et al.   NEURO-ONCOLOGY

Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

(2012) Igor Vivanco et al.   Cancer Discovery

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma

(2011) David A. Reardon et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia

(2011) M H Kirschbaum et al.   LEUKEMIA

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma

(2011) T. N. Kreisl et al.   NEURO-ONCOLOGY

Pathway inhibition: emerging molecular targets for treating glioblastoma

(2011) W. Wick et al.   NEURO-ONCOLOGY

Recurrent Glioblastoma: A Fresh Look at Current Therapies and Emerging Novel Approaches

(2011) Mark R. Gilbert   SEMINARS IN ONCOLOGY

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

(2010) Jennifer L. Clarke et al.   JOURNAL OF NEURO-ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

(2008) Michael D. Prados et al.   JOURNAL OF CLINICAL ONCOLOGY

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY